$XBI $65.68 | +3.56%
Table of Contents:
Covid Updates
#BNTX +2.4% & $PFE Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine .
Pipeline Updates
#ACAD +15.5% Acadia gains 19% on FDA briefing docs on antipsychotic therapy
#AQST +5.9% (+13.1% aftr mrkt) Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
#ADPT +11% Adaptive Biotechnologies Launches T-Detectâ„¢ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
#HZNP +10.8% Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil.
#IMAB +8.1% I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210.
#IMUX +5.3% Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
#OMGA +4.3% Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma.
#HEPA +4.2% Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congressâ„¢ 2022
#JAZZ +1.9% Jazz Pharmaceuticals and Redx Announce Pan-RAF Inhibitor JZP815 to Enter Clinical Development
#ALNY +1.5% Alnylam Announces FDA Approval of AMVUTTRAâ„¢ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
#KYMR -1.9% Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#VECT -9.3% VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
Posted by FS/JM